Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: A double-blind controlled trial

Antiviral Therapy

Volumn 2, Issue 4, 1997, Pages 229-236

  Walker, M ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PLACEBO; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; AUSTRALIA; CELL COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL NEUROPATHY; PORTUGAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPAIN;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; ZALCITABINE; ZIDOVUDINE;

EID: 17344362826     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz M, Reves R, Loveless MO, Crane L, Thompson M & Abrams D. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immune deficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. New England Journal of Medicine 1996;335:1099-1106.
2. Delta Co-ordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine or zidovudine alone in HIV infected individuals. Lancet 1996; 348:283-290.
3. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS & Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200-500 per cubic millimeter. New England Journal of Medicine 1996; 335:1081-1090.
4. Lalezari J, Haubrich R, Burger HU, Beattie D, Donatacci L, Salgo MP & the NVI4256 Study Team. Improved survival and decreased disease progression of HIV in patients treated with saquinavir plus HIVID. IXth International Conference on AIDS, Vancouver, Canada July 1996. Abstract LB. B.6033
5. Caesar Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-1421.